Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Obese Adult Patients With Schizophrenia Taking Antipsychotic Medications (GRATITUDE II)

NCT04524403 is registered in ClinicalTrials.gov with Corcept Therapeutics as lead sponsor.

NCT NCT04524403
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04524403 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Obese Adult Patients With Schizophrenia Taking Antipsychotic Medications (GRATITUDE II)
Lead sponsor
Corcept Therapeutics
Phase
Phase 2
Overall status
Completed
Start date
September 9, 2020
Completion date
August 25, 2022
Enrollment
150 (actual)
Sites
40

Conditions

As the registry lists them; a condition with its own page is linked.

antipsychotic-induced weight gain (aiwg)